Tolerance of 24-hour infusions or low- and high-dose bolus injections of adriamycin in children.
In 75 children with mainly lymphoid malignancies, adriamycin was used as part of the treatment. Three groups were distinguished: group I (n = 18), with an adriamycin dose of 30 mg/m2 as bolus; group II (n = 30), with a dose of 100 mg/m2 divided over 2 subsequent days; and group III (n = 27), with a dose of adriamycin of 100 mg/m2 given as a 24-h infusion. The tolerance of the low dose was the best. In group III small differences in the tolerance were observed. The recovery of the white blood cell count showed a delay in the infusion group, whereas the bolus injection group showed more vomiting. Severe vascular lesions occurred in the infusion group. The use of 24-h infusions of adriamycin is feasible when central venous accesses or totally subcutaneous intravenous devices are used. According to the literature, when long-term invasions of adriamycin are used, the risk of cardiomyopathy is diminished, without influencing the antitumor activity of adriamycin.
Lippens
R J
RJ
Department of Pediatrics, St. Radboud Academic Hospital, University of Nijmegen, The Netherlands.
van Lier
H J
HJ
Zwagemakers
J F
JF
D001855:Bone Marrow Diseases / Q000139:chemically induced*; D002114:Calcinosis / Q000139:chemically induced; D002648:Child; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D009369:Neoplasms / Q000188:drug therapy; D012189:Retrospective Studies; D014680:Veins / Q000293:injuries
D004317:Doxorubicin